overactive bladder
Conditions
Interventions
None listed
Sponsors
Department of Urology, University of Yamanashi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following. Patients who visited the department of urology of the research collaborating hospitals from the date of approval by the head of the research institution to July 31,2025. Over 80 years old. Patients scheduled to receive vibegron. Urinary urgency score 2 or over and total score 3 or over on the overactive bladder symptom score. Patients who give written consent to participate in this study.
Exclusion criteria
Exclusion criteria: Patients with any of the following. long QT syndrome. Patients with a history of serious cardiac disease. Patients with severe abdominal pressure incontinence. Patients with residual urine volume over 100 mL, severe dysuria, active urinary tract infection, bladder stones, or urinary tract malignancy. Patients scheduled to continue treatment with mirabegron. Patients who are determined to be ineligible by a physician's judgment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overactive Bladder Symptom Score (OABSS) at 4, 8 and 12 weeks after starting treatment with vibegron. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events, International Prostate Symptom Score (IPSS), Overactive Bladder Questionnaire (OAB-q), Mini-Mental State Examination (MMSE), Vulnerable Elders Survey-13 (VES-13), uroflowmetry, and residual urine measurement at 4, 8 and 12 weeks after starting treatment with vibegron. | — |
Countries
Japan
Contacts
Public ContactHiroshi Shimura
University of Yamanashi Department of Urology
Outcome results
None listed